Skip to main content
Clinical Trials/NCT01361399
NCT01361399
Completed
Phase 3

A 4-arm, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Single Dose, Parallel Group Study Comparing Efficacy and Safety of a Fixed Combination of 500 mg Acetylsalicylic Acid + 4 mg Lidocaine With 500 mg Acetylsalicylic Acid and 4 mg Lidocaine Monotherapy as Well as Placebo in Adult Patients With Sore Throat Associated With a Common Cold.

Bayer0 sites1,088 target enrollmentNovember 30, 2004

Overview

Phase
Phase 3
Intervention
Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Conditions
Common Cold
Sponsor
Bayer
Enrollment
1088
Primary Endpoint
Sum of pain intensity differences SPID
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to investigate the analgesic efficacy of a single dose of a fixed combination of 500 mg Aspirin (Acetylsalicylic Acid) and 4 mg Lidocaine in adult patients with sore throat associated with a common cold in comparison to a single treatment with 500 mg Aspirin or 4 mg Lidocaine alone as well a Placebo (treatment without any active ingredient). The combination of Aspirin and Lidocaine in a single lozenge is expected to provide relief from sore throat pain by sequential action. A very fast inset of action will be achieved by the locally acting Lidocaine and a long duration of action will be achieved by the systemically acting Aspirin.

Registry
clinicaltrials.gov
Start Date
November 30, 2004
End Date
May 28, 2005
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Bayer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males and females of at least 18 years of age
  • Onset of common cold within the last 3 days (12 to 72 hours)
  • History of at least 4 symptoms associated with URTI in the last 24 hours out of runny nose, stuffy nose, sneezing, wet cough, dry cough, sweating, earache, ear fullness, sinus pressure/pain, head heaviness, muscle aches and pains, feverish discomfort, chills, hoarseness, sore throat, scratchy throat and headache as documented in the history of URTI
  • Current sore throat confirmed by a score ≥ 6 on a 11-category vertical ordinal scale for sore throat pain
  • Findings that confirmed the presence of tonsillopharyngitis

Exclusion Criteria

  • Pregnancy (i.e. positive pregnancy test at baseline)
  • Breastfeeding
  • History of hypersensitivity (allergic reaction) to ASA or any other NSAID
  • History of hypersensitivity (allergic reaction) to lidocaine
  • History or acute state of peptic ulceration or gastrointestinal bleeding
  • History of bleeding tendency
  • History of asthma
  • Clinical diagnosis of chickenpox or influenza
  • History or presence of severe liver or kidney disease
  • Intake of short-acting analgesics (e.g. ASA, paracetamol, ibuprofen, diclofenac) either as a single ingredient or as part of a combination cold product in the last 6 hours, or intake of long-acting analgesics (e.g. naproxen) in the last 12 hours, or intake of any other NSAID in the last 24 hours

Arms & Interventions

Arm 1

Intervention: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain

Arm 2

Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)

Arm 3

Intervention: Lidocain

Arm 4

Intervention: Placebo

Outcomes

Primary Outcomes

Sum of pain intensity differences SPID

Time Frame: 120 minutes

Pain intensity difference to baseline (PID12 min)

Time Frame: 12 minutes

Pain intensity difference to baseline (PID120 min)

Time Frame: 120 minutes

Secondary Outcomes

  • Pain intensity difference to baseline (PID)(3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose)
  • Total pain relief to baseline (TOTPAR)(3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose)
  • Assessment of safety and tolerability(240 minutes)
  • Symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches and pain)(60, 120, 180, and 240 minutes post dose)
  • Overall assessment of treatment(240 minutes)

Similar Trials